GlaxoSmithKline a global healthcare company that develops, manufactures and markets pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. I have a holding in my income portfolio (epic code: GSK).
GSK announced today that the US FDA has approved ANORO/ELLIPTA to be used as a once-daily, maintenance treatment of airflow obstruction in patients
with chronic obstructive pulmonary disease (COPD), including chronic bronchitis
and/or emphysema.
They stated that Anoro/Ellipta is not indicated for the relief of acute
bronchospasm or for the treatment of asthma.
Theravance (NASDAQ: THRX) who jointly developed this medication with GSK is obliged to
make a milestone payment of $30m to GSK following FDA approval. A further $30m payment to GSK will follow the launch of Anoro/Ellipta
in the US, expected in the first quarter 2014.
I make this 5 FDA approvals this year:
May 2013 - Trametinib (Mekinist)
May 2013 - Dabrafenib (Tafinlar)
May 2013 - Breo/Ellipta
August 2013 - Tivicay
December 2013 - Anora/Ellipta
I understand that there have been 34 approvals this year, so GSK appears to have a good share, this compares to 43 approvals last year. Although lower in number, a few analysts have said that the expected sales by their fifth year for 2013 approvals, will be up to 14% higher than last year
No comments:
Post a Comment